By Topic

Analysis of gene expression in gemcitabine resistant cells derived from human pancreatic cancer cell

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$33 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

7 Author(s)
Shaoxuan Zhang ; Lab. of Mol. Genetics, Jilin Univ., Changchun, China ; Tatsuhiko Furugawa ; Homare Takahashi ; Xiaofang Che
more authors

To analyze the expression of genes involved in gemcitabine-resistant cells derived from human pancreatic cancer cell, we established several cell lines with different acquired resistance to gemcitabine from pancreatic cancer cell line MIA-PaCa2, and analyzed the expression of the genes that are considered to be associated with the resistance to gemcitabine using PCR and real-time PCR. We found that in these gemcitabine-resistant cell lines, the expression of human equilibrative nucleoside transporter 2 (hENT2) and deoxycytidine deaminase (DCTD) was lower than that of the parental cell line MIA-PaCa2 in the earlier stage of the cells incubated with 300nM gemcitabine; and, in the later stage, the expression of hENT2 recovered, but the expression levels of ribonucletide reductase subunit M1 (RRM1) and M2 (RRM2) were increased. These findings suggest that the decreased accumulation of gemcitabine and the increased expression of RRM1 and RRM2 are involved in gemcitabine-resistance formation in MIA-PaCa2.

Published in:

Human Health and Biomedical Engineering (HHBE), 2011 International Conference on

Date of Conference:

19-22 Aug. 2011